Trial Profile

A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 22 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aripiprazole (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

11 Apr 2022 Primary endpoint (Percentage of Participants With Inpatient Psychiatric Hospitalization) has been met according to the results published in the Journal of Clinical Psychiatry
11 Apr 2022 Results published in the Journal of Clinical Psychiatry
05 Oct 2021 Results presented at the 34th Annual Congress of the European College of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com